1. Home
  2. ARTL vs CPHI Comparison

ARTL vs CPHI Comparison

Compare ARTL & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARTL
  • CPHI
  • Stock Information
  • Founded
  • ARTL 2011
  • CPHI N/A
  • Country
  • ARTL United States
  • CPHI China
  • Employees
  • ARTL N/A
  • CPHI N/A
  • Industry
  • ARTL Biotechnology: Pharmaceutical Preparations
  • CPHI Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARTL Health Care
  • CPHI Health Care
  • Exchange
  • ARTL Nasdaq
  • CPHI Nasdaq
  • Market Cap
  • ARTL 3.8M
  • CPHI 4.0M
  • IPO Year
  • ARTL N/A
  • CPHI N/A
  • Fundamental
  • Price
  • ARTL $1.16
  • CPHI $0.21
  • Analyst Decision
  • ARTL Strong Buy
  • CPHI
  • Analyst Count
  • ARTL 2
  • CPHI 0
  • Target Price
  • ARTL $5.50
  • CPHI N/A
  • AVG Volume (30 Days)
  • ARTL 33.2K
  • CPHI 701.9K
  • Earning Date
  • ARTL 03-24-2025
  • CPHI 03-31-2025
  • Dividend Yield
  • ARTL N/A
  • CPHI N/A
  • EPS Growth
  • ARTL N/A
  • CPHI N/A
  • EPS
  • ARTL N/A
  • CPHI N/A
  • Revenue
  • ARTL N/A
  • CPHI $5,544,620.00
  • Revenue This Year
  • ARTL N/A
  • CPHI N/A
  • Revenue Next Year
  • ARTL N/A
  • CPHI N/A
  • P/E Ratio
  • ARTL N/A
  • CPHI N/A
  • Revenue Growth
  • ARTL N/A
  • CPHI N/A
  • 52 Week Low
  • ARTL $0.91
  • CPHI $0.13
  • 52 Week High
  • ARTL $1.70
  • CPHI $0.50
  • Technical
  • Relative Strength Index (RSI)
  • ARTL 43.72
  • CPHI 48.21
  • Support Level
  • ARTL $1.15
  • CPHI $0.19
  • Resistance Level
  • ARTL $1.24
  • CPHI $0.24
  • Average True Range (ATR)
  • ARTL 0.10
  • CPHI 0.02
  • MACD
  • ARTL -0.02
  • CPHI 0.00
  • Stochastic Oscillator
  • ARTL 2.50
  • CPHI 46.67

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: